SCHEMBL7688700

SCHEMBL7688700

Cc1cc(-c2ccccc2)n(C)c1C(=O)O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.45
KMT2A Q03164 1/20 0.44
HPGD P15428 1/20 0.44
GRIA4 P48058 2/20 0.43
TP53 P04637 1/20 0.43
GRIA2 P42262 1/20 0.43
PKM P14618 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.41
CCNB2 O95067 1/20 0.40
CDK1 P06493 1/20 0.40
CCNB1 P14635 1/20 0.40
CDK5 Q00535 1/20 0.40
CDK5R1 Q15078 1/20 0.40
CCNB3 Q8WWL7 1/20 0.40
ADORA2B P29275 1/20 0.40
NQO2 P16083 1/20 0.40
RPA1 P27694 2/20 0.39
MYC P01106 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28850533 0.86 NQO2 (0.44) ALDH1A1KMT2AHPGDTP53CCNB2
Hydrochloric Acid SCHEMBL16241844 0.85 NQO2 (0.43) ALDH1A1KMT2AHPGDTP53CCNB2
SCHEMBL2214810 0.75 NOTUM (0.50) ALDH1A1KMT2AHPGDKDM4EMYC
SCHEMBL28630613 0.75 KMT2A (0.52) ALDH1A1KMT2AHPGDKDM4ECCNB2
SCHEMBL9955427 0.72 NR4A1 (0.39) ALDH1A1KMT2AKDM4EMAPTMYC
SCHEMBL10046853 0.72 FNTA (0.44) ALDH1A1HPGDMAPT
SCHEMBL7329614 0.71 KMT2A (0.44) ALDH1A1KMT2AHPGDKDM4ECCNB2
SCHEMBL10463696 0.71 HPGD (0.51) ALDH1A1KMT2AHPGDPKMKDM4E
SCHEMBL11193555 0.71 HSD17B10 (0.46) ALDH1A1KMT2AHPGDKDM4EMAPT
SCHEMBL27414914 0.70 MAPK1 (0.56) ALDH1A1KMT2ATP53MAPTHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020042428-A1 Quinuclidine-substituted heteroaryl moieties for treatment of disease PHARMACIA & UPJOHN COMPANY 2002-04-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020042428-A1 Quinuclidine-substituted heteroaryl moieties for treatment of disease NQO2, GBA1, UGT1A1 ALDH1A1 130/4885KMT2A 3388/4885HPGD 581/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.